Indian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....

Investors have a final chance today to purchase shares in Tata Chemicals, Tata Elxsi, and Tata Investment Corporation. These three Tata Gro...

Indian equity markets experienced a significant sell-off on Monday, with the Sensex and Nifty declining around 1% each. This downturn was d...

Wall Street experienced a sharp decline on Friday, led by the Nasdaq's significant fall, as a robust US jobs report fueled concerns about s...

Hindustan Zinc shares fell sharply on Friday after a report said the government may sell up to a 2% stake in the company to raise around Rs...

Japan's Nikkei index experienced its biggest drop in three weeks on Thursday. This pullback followed a record high. Investors sold AI-relat...

Indian smallcap and midcap stocks plummeted on Wednesday due to persistent FII selling, a weakening rupee, and global factors. IT stocks, w...

Indian stock market staged a sharp recovery, with Sensex and Nifty erasing morning losses to snap a four-session losing streak, led by a st...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

NHPC Share Price: NHPC shares saw a significant drop of nearly 5 percent. This decline followed the government's launch of an offer for sal...

The Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while re...